No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 4.3x · 10Y median 4.6x · 39th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 22
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:08.653Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Invivyd, Inc. (IVVD) stock was $0.84 as of Oct 6, 2026, 10:00 AM EDT, up 0.41% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -27.5% · 3-year avg -19.9%/yr · 5-year avg -51.7%/yr
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease.
Biotechnology · New Haven, CT
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.11
Revenue Est.
$15.04M
Last Quarter Results
EPS
$-0.14
vs Estimate
$-0.11
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IVVD | $248.24M | $0.84 | +0.41% | -27.54% | -51.69% | N/A | N/A |
| 2GLSI | $247.00M | $16.83 | -0.48% | +54.67% | -14.84% | N/A | vs IVVD |
| 3LFCR | $244.19M | $6.51 | -0.15% | -6.56% | -7.12% | -6.99% | vs IVVD |
| 4BDSX | $244.13M | $29.99 | +3.20% | +273.09% | -28.49% | N/A | vs IVVD |
| 5IFRX | $243.03M | $1.65 | -1.79% | +6.30% | -7.34% | N/A | vs IVVD |
| 6CAMP | $242.23M | $3.86 | -3.74% | +32.17% | N/A | N/A | vs IVVD |
N/A
$14.29M
vs Estimate
$14.40M
Consensus Rating
Based on 3 analysts
Average Price Target
$10.00
+1086.8% upside
Low
$10.00
Current
$0.84
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.15 | $-0.13 | $-0.12 | 1 |
| Quarter ending Dec 2026 | $-0.14 | $-0.12 | $-0.11 | 1 |
| Quarter ending Mar 2027 | $-0.09 | $-0.08 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.09 | $-0.08 | $-0.07 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.58 | $-0.53 | $-0.47 | 2 |
| FY 2027 | $-0.42 | $-0.33 | $-0.24 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $14.11M | $15.04M | $16.74M | 2 |
| Quarter ending Dec 2026 | $15.93M | $16.97M | $18.89M | 2 |
| Quarter ending Mar 2027 | $15.95M | $17.00M | $18.92M | 1 |
| Quarter ending Jun 2027 | $16.38M | $17.45M | $19.42M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $52.18M | $60.05M | $68.16M | 2 |
| FY 2027 | $75.58M | $86.98M | $98.73M | 2 |
